Bayer commences cash tender offer for all outstanding shares of Conceptus, Inc.

  Bayer commences cash tender offer for all outstanding shares of Conceptus,
                                     Inc.

PR Newswire

LEVERKUSEN, Germany and WAYNE, N.J., May 7, 2013

LEVERKUSEN, Germanyand WAYNE, N.J., May 7, 2013 /PRNewswire/ --Bayer's
planned acquisition of Conceptus, Inc., based in Mountain View, California
(NASDAQ: CPTS) is entering its next phase: Evelyn Acquisition Company, a
subsidiary established by Bayer HealthCare LLC, Tarrytown, N.Y., for the
purpose of the acquisition, is commencing today a cash tender offer for all
the shares of Conceptus, Inc. at a price of US$31.00 per share. The total
value of the transaction amounts to approximately US$ 1.1 billion (equivalent
to EUR 852 million). The board of directors of Conceptus has unanimously
recommended that its stockholders accept the offer, which expires at 12:00
midnight, New York City time on June 5, 2013 (one minute after 11:59 p.m., New
York City time, on June 4, 2013), unless the tender offer is extended or
earlier terminated by Bayer in accordance with the Merger Agreement (defined
below). Completion of the tender offer is conditioned upon a minimum tender of
at least a majority of Conceptus' outstanding shares (on a fully diluted
basis), antitrust clearance in the United States, and other closing conditions
specified in the Offer to Purchase, dated May 7, 2013, which was filed by
Bayer with the U.S. Securities and Exchange Commission (the "SEC") today.

The tender offer is being made pursuant to an Agreement and Plan of Merger,
dated as of April 28, 2013 (the "Merger Agreement"), which Bayer announced on
April 29, 2012. Conceptus has developed Essure^®, the only non-surgical
permanent birth control method, which it markets in the U.S. and other
countries. Following the acquisition, Bayer will be able to offer a complete
range of short-term, long-term and permanent contraceptive choices for women.

Bayer, Bayer HealthCare LLC, and Evelyn Acquisition Company filed with the SEC
today a Tender Offer Statement on Schedule TO (the "Schedule TO"), including
an Offer to Purchase (the "Offer to Purchase"), a related Letter of
Transmittal (the "Letter of Transmittal") and other related materials, setting
forth in detail the complete terms and conditions of the tender offer.
Additionally, Conceptus filed with the SEC today a Solicitation/Recommendation
Statement on Schedule 14D-9 related to the tender offer.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the fields of health
care, agriculture and high-tech materials. As an innovation company, it sets
trends in research-intensive areas. Bayer's products and services are designed
to benefit people and improve the quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and acts as a
socially and ethically responsible corporate citizen. In fiscal 2012, the
Group employed 110,500 people and had sales of EUR 39.8 billion. Capital
expenditures amounted to EUR 2.0 billion, R&D expenses to EUR 3.0 billion. For
more information, go to www.bayer.com.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the
world's leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec
31, 2012) and is represented in more than 100 countries. More information at
www.healthcare.bayer.com.

IMPORTANT INFORMATION ABOUT THE OFFER

The tender offer described in this press release has commenced, but this press
release is neither an offer to purchase nor a solicitation of an offer to sell
shares. The solicitation and the offer to buy all of the outstanding Conceptus
shares is being made pursuant to the Tender Offer Statement on Schedule TO
filed by Bayer, Parent and Purchaser with the SEC on May 7, 2013. Conceptus
also filed a Solicitation/Recommendation Statement on Schedule 14D-9 with
respect to the tender offer with the SEC on May 7, 2013. Conceptus
stockholders and other investors are urged to read the relevant tender offer
documents (including an Offer to Purchase, a related Letter of Transmittal and
certain other offer documents) and the Solicitation/Recommendation Statement
because they contain important information, which should be read carefully
before any decision is made with respect to the tender offer. The Offer to
Purchase, the related Letter of Transmittal and certain other offer documents,
as well as the Solicitation/ Recommendation Statement, will be made available
to all stockholders of Conceptus, Inc. at no expense to them. The tender offer
documents and the Solicitation/Recommendation Statement are available for free
at the SEC's web site at www.sec.gov. Free copies of these materials will also
be available from the Information Agent.

In addition to the Solicitation/Recommendation Statement, Conceptus files
annual, quarterly and special reports, proxy statements and other information
with the SEC. You may read and copy any reports, statements or other
information filed by Conceptus at the SEC public reference room at 100 F
Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330
for further information on the public reference room. Conceptus' filings with
the SEC are also available to the public from commercial document-retrieval
services and at the website maintained by the SEC at www.sec.gov.

Forward-Looking Statements
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com.The company assumes no liability
whatsoever to update these forward-looking statements or to conform  them to
future events or developments.

Not intended for UK Media

SOURCE Bayer HealthCare

Website: http://www.bayer.com
Contact: Gunter Forneck, +49 214 30-50446, guenter.forneck@bayer.com